Table 2.

Cumulative incidence of efficacy endpoints during follow-up in the intention-to-treat population

	21 days		50 days		90 days
	Enoxaparin group (n=105)	Standard-of care-group (n=114)	Enoxaparin group (n=105)	Standard-of-care group (n=114)	Enoxaparin group (n=105)	Standard-of-care group (n=114)
All-cause death	1 (1%)	0	1 (1%)	1 (1%)	1 (1%)	1 (1%)
All-cause hospitalisation	12 (11%)	12 (11%)	12 (11%)	12 (11%)	12 (11%)	12 (11%)
Composite of all-cause death and all-cause hospitalisation	12 (11%)	12 (11%)	12 (11%)	12 (11%)	12 (11%)	12 (11%)
Venous thromboembolism	1 (1%)	1 (1%)	1 (1%)	2 (2%)	1 (1%)	2 (2%)